Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1356 • 2012 ACR/ARHP Annual Meeting
Gender Differences Among Spondylitis Associated with Psoriasis, Inflammatory Bowel Disease and Primary Ankylosing Spondylitis
Margarita Landi¹, Hernan Maldonado-Ficco², Jose A. Maldonado-Cocco², Gustavo Citera³, Pablo Arturi², Percival Sampaio-Barros⁴, Diana Flores⁵, Ruben Burgos-Vargas⁶, Helena Santos⁷, Jose Chavez-Corrales⁸, Daniel Palleiro⁹, Miguel A. Gutierrez¹⁰, Elsa Vieira-Sousa¹¹, Fernando Pimentel-Santos¹², Sergio O. Paira¹³, Alberto Berman Sr.¹⁴, Janitzia Vazquez-Mellado¹⁵, Eduardo Collantes-Estevez¹⁶ and On behalf of RESPONDIA Group¹⁷, ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitacion Psicofisica and Fundacion Reumatologica Argentina, Buenos Aires, Argentina, ³Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Rheumatology, Hospital Universitario, Monterrey, Mexico, ⁶Rheumatology, Hospital General de Mexico, Mexico DF, Mexico, ⁷Rheumatology, Instituto Português de Reumatologia, Lisboa, Portugal, ⁸Rheumatology, Hospital Nacional E. Rebagliti-ESSALUD, Lima, Peru, ⁹Rheumatology, Instituto Nacional de Reumatologia, Montevideo, Uruguay, ¹⁰Rheumatology and Inmunology, Pontificia Universidad Catolica de Chile, Santiago, Chile, ¹¹Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹²Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹³Hospital Jose María Cullen, Santa Fe SFE S3000BFP, Argentina, ¹⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ¹⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ¹⁶Depatamento de Medicina, IMIBIC-Reina Sofia Hospital, Cordoba 14012, Spain, ¹⁷Buenos Aires
Background/Purpose: Differences regarding gender in primary Ankylosing Spondylitis are well known. However, there is less evidence regarding Spondylitis Associated with Psoriasis and that associated with…
Abstract Number: 599 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin K, DKK-1 and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway
Alberto Cauli¹, Grazia Dessole¹, Giovanni Porru¹, Matteo Piga¹, Alessandra Vacca², Valentina Ibba¹, Pietro Garau¹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology Unit - Medical Sciences, University of Cagliari, Cagliari, Italy
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory arthritis characterized by erosions and new bone formation. These processes appear to be related by the fine balance…
Abstract Number: 2219 • 2012 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates After One Year of Treatment with Etanercept – results of the Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel¹, Christian Althoff³, Denis Poddubnyy⁴, Joachim Listing⁵, Anja Weiß⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum Berlin, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration < 5 years we assessed whether there is a difference to etanercept (ETA)…
Abstract Number: 1363 • 2012 ACR/ARHP Annual Meeting
Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis
Carmen Stolwijk¹, A.M. Van Tubergen², Sofia Ramiro³, Ivette Essers¹, Marc Blaauw¹, Désirée van der Heijde⁴, Robert B. M. Landewé⁵, Filip Van den Bosch⁶, Maxime Dougados⁷ and Annelies Boonen⁸, ¹Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ⁶Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Comorbidities can importantly influence the results of clinical studies on functional outcomes as they may act as confounders or effect modifiers. The generic self-administered…
Abstract Number: 571 • 2012 ACR/ARHP Annual Meeting
Description of Distribution of Active Inflammatory Lesions On Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine in Patients with Early Axial Spondyloarthritis – Analysis of the Esther Trial Baseline Data
In-Ho Song¹, Christian Althoff², Hildrun Haibel¹, Joachim Listing³, Anja Weiß⁴, Bruce Freundlich⁵, Martin Rudwaleit⁶ and Joachim Sieper⁷, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴German Rheumatism Research Centre, Berlin, Germany, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Endokrinologikum Berlin, Berlin, Germany, ⁷Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To address the question whether active inflammation starts at specific sites of the sacroiliac joints (SI-joints) and/ or the spine. Methods: Wb-MRIs of…
Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting
Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry
Andreas M. Reimold¹, Liron Caplan², Daniel O. Clegg³, Gail S. Kerr⁴, Elizabeth Chang⁵, Lisa A. Davis⁶, Prashant Kaushik⁷, Vikas Majithia⁸, J. Steuart Richards⁹, Joel D. Taurog¹⁰ and Jessica Walsh¹¹, ¹Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ²Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Phoenix VAHCS, Phoenix, AZ, ⁶Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁷Department of Medicine, Sratton VAMC, Albany, NY, ⁸Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁹Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ¹⁰Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Rheumatology, University of Utah Hospital, Salt Lake City, UT
Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints. The arthritis may present as the primary…
Abstract Number: 1366 • 2012 ACR/ARHP Annual Meeting
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo – Controlled Study
Chunde Bao¹, Feng Huang², Muhammad Asim Khan³, Kaiyin Fei⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, ⁴Janssen Research & Development, LLC., Spring House, PA
Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 24 Safety and Efficacy Results From a Randomized, Placebo-Controlled StudyBackground/Purpose: This…
Abstract Number: 575 • 2012 ACR/ARHP Annual Meeting
Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen², Morten Asser Karsdal³, Efstathios Vassiliadis⁴, Stephanie Wichuk⁵, Claus Christiansen⁶ and Walter P. Maksymowych⁷, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶CCBR, Ballerup, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Chronic inflammatory diseases such as Ankylosing Spondylitis (AS) are diverse and therefore hard to clearly diagnose and treat. Conventional biomarkers for AS, as CRP…
Abstract Number: 1925 • 2012 ACR/ARHP Annual Meeting
Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Susan Bolge¹, Helen Eldridge², Dilesh Doshi¹, Lorie Ellis³, Barbara Roland⁴ and John Woelfel⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ, ³Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁴The Dominion Group, Reston, VA
Title: Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Background/Purpose: Golimumab (GLM), adalimumab…
Abstract Number: 1372 • 2012 ACR/ARHP Annual Meeting
Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum Berlin, Berlin, Germany, ⁴UCB Pharma, Braine, Belgium, ⁵UCSD School of Medicine, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). AS significantly affects patients' (pts) work productivity.1 The impact of the…
Abstract Number: 583 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, I-Jun Chou⁶, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To estimate the risk of ankylosing spondylitis (AS) among individuals with affected first-degree relatives and to assess the magnitude of genetic contribution to the…
Abstract Number: 1851 • 2012 ACR/ARHP Annual Meeting
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Daniel E. Kreutz¹, Santosh P. Reddy¹, Guy P. Fiocco², Colleen Colbert³ and Juhee Song⁴, ¹Internal Medicine, Scott & White Healthcare/Texas A&M University, Temple, TX, ²Division of Rheumatology, Scott & White Clinic, Temple, TX, ³Graduate Education, Scott & White Healthcare/Texas A&M University, Temple, TX, ⁴Statistics, Scott & White Healthcare/Texas A&M University, Temple, TX
Background/Purpose: Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a source of significant morbidity/mortality. Health-care entities spend large amounts to prevent spread of MRSA. Most MRSA…
Abstract Number: 1373 • 2012 ACR/ARHP Annual Meeting
Influence of Early Onset On the Clinical Characteristics and Prognosis of Ankylosing Spondylitis
Maria Aparicio¹, Jesús Rodríguez-Moreno¹, Paula Estrada¹, Irene Martín-Esteve², Laura López-Vives¹, Vicenç Torrente³, Jordi Anton⁴, Joan Miquel Nolla⁵ and Xavier Juanola⁶, ¹Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ²Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ³Rheumatology, Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the influence of early onset (≤ 16 years) on the clinical characteristics and prognosis of ankylosing spondylitis (AS). Methods: We revised patients…
Abstract Number: 584 • 2012 ACR/ARHP Annual Meeting
Association of Platelet Endothelial Cell Adhesion Molecule-1 and â1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis
Seung Cheol Shim¹, Donghyuk Sheen², Mi Kyoung Lim¹ and Hyo Park¹, ¹Medicine, Eulji University Hospital, Daejeon, South Korea, ²Rheumatology, Eulji University Hospital, Daejeon, South Korea
Background/Purpose: Genetic factors provide over 90% of the susceptibility to ankylosing spondylitis (AS) and recent studies have focused on non-major histocompatibility complex genes. The etiology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.